Final results from the only European trial demonstrated a 1.4-month median survival improvement with irinotecan compared with etoposide (8.5 versus 7.1 months, P = 0.02) in patients with SCLC. 4 ...

Researchers divided the women into three groups depending on the severity of their cancer and treated them with an intensive regime of cisplatin and another drug called etoposide. The response ...

Subgroup analysis suggested that patients with large, localized tumors benefited from the addition of etoposide, whereas patients with metastases did not. There was no difference in EFS between ...